Welcome to LookChem.com Sign In|Join Free
  • or
(1'R,3'S,3S,5R,6R)-5-AMINO-2-AMINOMETHYL-6-(4,6-DIAMINO-2,3-DIHYDROXY-CYCLOHEXYLOXY)-TETRAHYDRO-PYRAN-3,4-DIOL is a complex organic compound with a unique molecular structure. It is characterized by its multiple chiral centers and functional groups, which contribute to its potential biological activities and applications.

3947-65-7

Post Buying Request

3947-65-7 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

3947-65-7 Usage

Uses

Used in Pharmaceutical Industry:
(1'R,3'S,3S,5R,6R)-5-AMINO-2-AMINOMETHYL-6-(4,6-DIAMINO-2,3-DIHYDROXY-CYCLOHEXYLOXY)-TETRAHYDRO-PYRAN-3,4-DIOL is used as a potential therapeutic agent for various medical conditions due to its unique molecular structure and functional groups. Its specific application reason is not provided in the materials, but its chiral centers and functional groups suggest that it may have potential in targeting specific biological pathways or receptors.
Used in Chemical Research:
(1'R,3'S,3S,5R,6R)-5-AMINO-2-AMINOMETHYL-6-(4,6-DIAMINO-2,3-DIHYDROXY-CYCLOHEXYLOXY)-TETRAHYDRO-PYRAN-3,4-DIOL can be used as a research tool in the field of organic chemistry and drug discovery. Its unique structure and chirality make it an interesting candidate for studying the effects of stereochemistry on biological activity and for developing new synthetic methods or strategies.

Check Digit Verification of cas no

The CAS Registry Mumber 3947-65-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,9,4 and 7 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 3947-65:
(6*3)+(5*9)+(4*4)+(3*7)+(2*6)+(1*5)=117
117 % 10 = 7
So 3947-65-7 is a valid CAS Registry Number.
InChI:InChI=1/C12H26N4O6/c13-2-5-8(18)9(19)6(16)12(21-5)22-11-4(15)1-3(14)7(17)10(11)20/h3-12,17-20H,1-2,13-16H2

3947-65-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name neamine

1.2 Other means of identification

Product number -
Other names neamin

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:3947-65-7 SDS

3947-65-7Synthetic route

(1S,2R,3R,4S,6R)-4,6-Diamino-3-((2R,3R,4R,5R,6R)-3-amino-6-aminomethyl-4,5-bis-benzyloxy-tetrahydro-pyran-2-yloxy)-cyclohexane-1,2-diol
549501-35-1

(1S,2R,3R,4S,6R)-4,6-Diamino-3-((2R,3R,4R,5R,6R)-3-amino-6-aminomethyl-4,5-bis-benzyloxy-tetrahydro-pyran-2-yloxy)-cyclohexane-1,2-diol

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
With hydrogen; 20% palladium hydroxide on carbon In water; acetic acid91%
With hydrogen; acetic acid; palladium dihydroxide
neomycin B
119-04-0

neomycin B

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
With hydrogenchloride In methanol for 6h; Heating;82%
With hydrogenchloride In methanol for 4h; Reflux;80%
Stage #1: neomycin B With hydrogenchloride; methanol for 16h; acidic methanolysis;
Stage #2: With Amberlite IRA-400 (OH-) In methanol for 0.5h; Hydrolysis;
67%
With water Acidic conditions; Inert atmosphere;
neomycin B trisulfate

neomycin B trisulfate

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
Stage #1: neomycin B trisulfate With hydrogenchloride In methanol for 6h; Heating;
Stage #2: With ammonium hydroxide; ammonia In methanol Further stages.;
70%
Conditions
ConditionsYield
With hydrogenchloride In methanol at 80℃; for 3h; pH=< 1;67%
neomycin B sulphate
25389-98-4

neomycin B sulphate

A

furfural
98-01-1

furfural

B

β-D-ribofuranose
36468-53-8

β-D-ribofuranose

C

neomycin A
3947-65-7

neomycin A

D

2,6-dideoxy-2,6-diamino-D-glucose
59433-00-0

2,6-dideoxy-2,6-diamino-D-glucose

E

(2R,3S,4R,5R,6R)-5-Amino-2-aminomethyl-6-((2R,3S,4R,5R)-4,5-dihydroxy-2-hydroxymethyl-tetrahydro-furan-3-yloxy)-tetrahydro-pyran-3,4-diol

(2R,3S,4R,5R,6R)-5-Amino-2-aminomethyl-6-((2R,3S,4R,5R)-4,5-dihydroxy-2-hydroxymethyl-tetrahydro-furan-3-yloxy)-tetrahydro-pyran-3,4-diol

Conditions
ConditionsYield
Product distribution; Rate constant; Irradiation; multistep reaction, radiolytic degradation;
neomycin B sulphate
25389-98-4

neomycin B sulphate

A

furfural
98-01-1

furfural

B

β-D-ribofuranose
36468-53-8

β-D-ribofuranose

C

neomycin A
3947-65-7

neomycin A

D

(2S,3R,4R,5S,6S)-3-Amino-6-aminomethyl-tetrahydro-pyran-2,4,5-triol

(2S,3R,4R,5S,6S)-3-Amino-6-aminomethyl-tetrahydro-pyran-2,4,5-triol

E

(2S,3S,4R,5R,6R)-5-Amino-2-aminomethyl-6-((2R,3S,4R,5R)-4,5-dihydroxy-2-hydroxymethyl-tetrahydro-furan-3-yloxy)-tetrahydro-pyran-3,4-diol

(2S,3S,4R,5R,6R)-5-Amino-2-aminomethyl-6-((2R,3S,4R,5R)-4,5-dihydroxy-2-hydroxymethyl-tetrahydro-furan-3-yloxy)-tetrahydro-pyran-3,4-diol

Conditions
ConditionsYield
Product distribution; Rate constant; Irradiation; multistep reaction, radiolytic degradation;
neomycin-B

neomycin-B

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
With hydrogenchloride; methanol
With hydrogenchloride
1,3,4,6-tetra-O-acetyl-2-azido-2-deoxy-D-glucopyranose
171032-74-9

1,3,4,6-tetra-O-acetyl-2-azido-2-deoxy-D-glucopyranose

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1: 90 percent / ZnI2 / 1,2-dichloro-ethane / 50 °C
2: 98 percent / NaOMe / methanol
3: 94 percent / pyridine
4: 100 percent / NaN3 / dimethylformamide / 80 °C
5: 86 percent / NaH / dimethylformamide
6: N-iodosuccinimide; silver trifluoromethanesulfonate / diethyl ether; CH2Cl2 / -20 °C
7: NaOMe / methanol
8: P(CH3)3; 0.1 N aq. NaOH / tetrahydrofuran
9: H2; aq. AcOH / 20 percent Pd(OH)2/C
View Scheme
phenyl 2-azido-2-deoxy-1-thio-α/β-D-glucopyranoside
202462-37-1

phenyl 2-azido-2-deoxy-1-thio-α/β-D-glucopyranoside

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 94 percent / pyridine
2: 100 percent / NaN3 / dimethylformamide / 80 °C
3: 86 percent / NaH / dimethylformamide
4: N-iodosuccinimide; silver trifluoromethanesulfonate / diethyl ether; CH2Cl2 / -20 °C
5: NaOMe / methanol
6: P(CH3)3; 0.1 N aq. NaOH / tetrahydrofuran
7: H2; aq. AcOH / 20 percent Pd(OH)2/C
View Scheme
phenyl 2-azido-2-deoxy-3,4,6-tri-O-acetyl-1-thio-α/β-D-glucopyranoside
183875-22-1

phenyl 2-azido-2-deoxy-3,4,6-tri-O-acetyl-1-thio-α/β-D-glucopyranoside

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1: 98 percent / NaOMe / methanol
2: 94 percent / pyridine
3: 100 percent / NaN3 / dimethylformamide / 80 °C
4: 86 percent / NaH / dimethylformamide
5: N-iodosuccinimide; silver trifluoromethanesulfonate / diethyl ether; CH2Cl2 / -20 °C
6: NaOMe / methanol
7: P(CH3)3; 0.1 N aq. NaOH / tetrahydrofuran
8: H2; aq. AcOH / 20 percent Pd(OH)2/C
View Scheme
phenyl 2,6-diazido-2,6-dideoxy-1-thio-α/β-D-glucopyranoside
632330-84-8

phenyl 2,6-diazido-2,6-dideoxy-1-thio-α/β-D-glucopyranoside

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 86 percent / NaH / dimethylformamide
2: N-iodosuccinimide; silver trifluoromethanesulfonate / diethyl ether; CH2Cl2 / -20 °C
3: NaOMe / methanol
4: P(CH3)3; 0.1 N aq. NaOH / tetrahydrofuran
5: H2; aq. AcOH / 20 percent Pd(OH)2/C
View Scheme
Toluene-4-sulfonic acid (2R,3S,4R,5R)-5-azido-3,4-dihydroxy-6-phenylsulfanyl-tetrahydro-pyran-2-ylmethyl ester
632330-83-7

Toluene-4-sulfonic acid (2R,3S,4R,5R)-5-azido-3,4-dihydroxy-6-phenylsulfanyl-tetrahydro-pyran-2-ylmethyl ester

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 100 percent / NaN3 / dimethylformamide / 80 °C
2: 86 percent / NaH / dimethylformamide
3: N-iodosuccinimide; silver trifluoromethanesulfonate / diethyl ether; CH2Cl2 / -20 °C
4: NaOMe / methanol
5: P(CH3)3; 0.1 N aq. NaOH / tetrahydrofuran
6: H2; aq. AcOH / 20 percent Pd(OH)2/C
View Scheme
(3R,4R,5R,6R)-3-Azido-6-azidomethyl-4,5-bis-benzyloxy-2-phenylsulfanyl-tetrahydro-pyran
549501-23-7

(3R,4R,5R,6R)-3-Azido-6-azidomethyl-4,5-bis-benzyloxy-2-phenylsulfanyl-tetrahydro-pyran

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: N-iodosuccinimide; silver trifluoromethanesulfonate / diethyl ether; CH2Cl2 / -20 °C
2: NaOMe / methanol
3: P(CH3)3; 0.1 N aq. NaOH / tetrahydrofuran
4: H2; aq. AcOH / 20 percent Pd(OH)2/C
View Scheme
3′,4′-di-O-benzyl-1,3,2′,6′-tetraazidoneamine
549501-27-1

3′,4′-di-O-benzyl-1,3,2′,6′-tetraazidoneamine

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: P(CH3)3; 0.1 N aq. NaOH / tetrahydrofuran
2: H2; aq. AcOH / 20 percent Pd(OH)2/C
View Scheme
Multi-step reaction with 2 steps
1: trimethylphosphane / tetrahydrofuran
2: hydrogen / 20% palladium hydroxide on carbon / water; acetic acid
View Scheme
5,6-di-O-acetyl-3',4'-di-O-benzyl-1,3,2',3'-tetraazidoneamine
549501-26-0

5,6-di-O-acetyl-3',4'-di-O-benzyl-1,3,2',3'-tetraazidoneamine

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: NaOMe / methanol
2: P(CH3)3; 0.1 N aq. NaOH / tetrahydrofuran
3: H2; aq. AcOH / 20 percent Pd(OH)2/C
View Scheme
neomycin B sulphate
25389-98-4

neomycin B sulphate

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
With hydrogenchloride
butan-1-ol
71-36-3

butan-1-ol

neomycin A
3947-65-7

neomycin A

Conditions
ConditionsYield
With acetic acid
neomycin A
3947-65-7

neomycin A

benzyl chloroformate
501-53-1

benzyl chloroformate

N,N',N'',N'''-tetra(benzyloxycarbonyl)neamine
22854-75-7

N,N',N'',N'''-tetra(benzyloxycarbonyl)neamine

Conditions
ConditionsYield
With sodium carbonate In acetone95%
With sodium hydrogencarbonate In acetone; toluene at 4℃;86%
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

neomycin A
3947-65-7

neomycin A

{(1R,2S,3R,4R,5S)-5-tert-Butoxycarbonylamino-4-[(2R,3R,4R,5S,6R)-3-tert-butoxycarbonylamino-6-(tert-butoxycarbonylamino-methyl)-4,5-dihydroxy-tetrahydro-pyran-2-yloxy]-2,3-dihydroxy-cyclohexyl}-carbamic acid tert-butyl ester
54230-72-7

{(1R,2S,3R,4R,5S)-5-tert-Butoxycarbonylamino-4-[(2R,3R,4R,5S,6R)-3-tert-butoxycarbonylamino-6-(tert-butoxycarbonylamino-methyl)-4,5-dihydroxy-tetrahydro-pyran-2-yloxy]-2,3-dihydroxy-cyclohexyl}-carbamic acid tert-butyl ester

Conditions
ConditionsYield
95%
C22H31N3O8

C22H31N3O8

neomycin A
3947-65-7

neomycin A

C25H48N6O11

C25H48N6O11

Conditions
ConditionsYield
In water; acetone for 1h;92%
C21H30N2O7

C21H30N2O7

neomycin A
3947-65-7

neomycin A

C24H47N5O10
936707-05-0

C24H47N5O10

Conditions
ConditionsYield
In water; acetone for 1h;92%
C27H24N2O6

C27H24N2O6

neomycin A
3947-65-7

neomycin A

C30H41N5O9
936707-01-6

C30H41N5O9

Conditions
ConditionsYield
In water; acetone for 1h;91%
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

neomycin A
3947-65-7

neomycin A

1,3,2',6'-tetra-N-(tert-butoxycarbonyl)neamine

1,3,2',6'-tetra-N-(tert-butoxycarbonyl)neamine

Conditions
ConditionsYield
With triethylamine In methanol; water at 20℃; for 2h;91%
neomycin A
3947-65-7

neomycin A

2-Chloro-benzoic acid (1R,2S,6R,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.02,6]dec-8-en-4-yl ester
100898-23-5

2-Chloro-benzoic acid (1R,2S,6R,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.02,6]dec-8-en-4-yl ester

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-2-chloro-benzamide

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-2-chloro-benzamide

Conditions
ConditionsYield
In water; acetonitrile for 0.5h; sonication;90%
In water; acetonitrile at 20℃; for 0.5h;90 %Chromat.
neomycin A
3947-65-7

neomycin A

1,3,2′,6′-tetraazidoneamine
671809-10-2

1,3,2′,6′-tetraazidoneamine

Conditions
ConditionsYield
With triflic azide; copper(II) sulfate; triethylamine In methanol; dichloromethane; water Inert atmosphere;90%
With triflic azide; copper(II) ion77%
With triflic azide; copper(II) sulfate; triethylamine
γ-L-Glu-((S)-4-amino-2-hydroxybutyryl)-N-acetylcysteamine thioester
1064665-41-3

γ-L-Glu-((S)-4-amino-2-hydroxybutyryl)-N-acetylcysteamine thioester

neomycin A
3947-65-7

neomycin A

γ-L-Glu-[(S)-4-amino-2-hydroxybutyryl]-neamine
1141768-83-3

γ-L-Glu-[(S)-4-amino-2-hydroxybutyryl]-neamine

Conditions
ConditionsYield
With recombinant BtrH enzyme at 20℃; for 6h; pH=7.9; aq. buffer; Enzymatic reaction;90%
C26H22N2O6

C26H22N2O6

neomycin A
3947-65-7

neomycin A

C29H39N5O9
936707-00-5

C29H39N5O9

Conditions
ConditionsYield
In water; acetone for 1h;89%
neomycin A
3947-65-7

neomycin A

Boc-β-Ala-ONB
65785-41-3

Boc-β-Ala-ONB

C20H39N5O9
936707-03-8

C20H39N5O9

Conditions
ConditionsYield
In water; acetone for 1h;87%
Naphthalen-1-yl-acetic acid (1R,2S,6R,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.02,6]dec-8-en-4-yl ester

Naphthalen-1-yl-acetic acid (1R,2S,6R,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.02,6]dec-8-en-4-yl ester

neomycin A
3947-65-7

neomycin A

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-2-naphthalen-1-yl-acetamide

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-2-naphthalen-1-yl-acetamide

Conditions
ConditionsYield
In water; acetonitrile for 0.5h; sonication;85%
In water; acetonitrile at 20℃; for 0.5h;85%
neomycin A
3947-65-7

neomycin A

N-benzoyloxy-5-norbornene-endo-2,3-dicarboximide
24147-30-6

N-benzoyloxy-5-norbornene-endo-2,3-dicarboximide

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-benzamide

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-benzamide

Conditions
ConditionsYield
In water; acetonitrile for 0.5h; sonication;80%
In water; acetone for 1h;80%
In water; acetonitrile at 20℃; for 0.5h;80%
neomycin A
3947-65-7

neomycin A

trityl chloride
76-83-5

trityl chloride

(2R,3S,4R,5R,6R)-6-[(1R,2R,3S,4R,6S)-2,3-Dihydroxy-4,6-bis-(trityl-amino)-cyclohexyloxy]-5-(trityl-amino)-2-[(trityl-amino)-methyl]-tetrahydro-pyran-3,4-diol

(2R,3S,4R,5R,6R)-6-[(1R,2R,3S,4R,6S)-2,3-Dihydroxy-4,6-bis-(trityl-amino)-cyclohexyloxy]-5-(trityl-amino)-2-[(trityl-amino)-methyl]-tetrahydro-pyran-3,4-diol

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide77%
C12H9NO4

C12H9NO4

neomycin A
3947-65-7

neomycin A

C15H26N4O7

C15H26N4O7

Conditions
ConditionsYield
In water; acetone for 1h;77%
neomycin A
3947-65-7

neomycin A

trifluoroacetic anhydride
407-25-0

trifluoroacetic anhydride

1,2',3,6'-tetrakis-N-(trifluoroacetyl)neamine
61066-03-3

1,2',3,6'-tetrakis-N-(trifluoroacetyl)neamine

Conditions
ConditionsYield
With triethylamine In acetonitrile for 1h; Ambient temperature;75.3%
neomycin A
3947-65-7

neomycin A

Phenyl-acetic acid (1R,2S,6R,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.02,6]dec-8-en-4-yl ester
100898-22-4

Phenyl-acetic acid (1R,2S,6R,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.02,6]dec-8-en-4-yl ester

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-2-phenyl-acetamide

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-2-phenyl-acetamide

Conditions
ConditionsYield
In water; acetonitrile for 0.5h; sonication;75%
In water; acetonitrile at 20℃; for 0.5h;75%
C11H10N4O4

C11H10N4O4

neomycin A
3947-65-7

neomycin A

C14H27N7O7

C14H27N7O7

Conditions
ConditionsYield
In water; acetone for 1h;75%
neomycin A
3947-65-7

neomycin A

N-benzyloxycarbonyloxy-5-norbornene-endo-2,3-dicarboximide
1092494-97-7

N-benzyloxycarbonyloxy-5-norbornene-endo-2,3-dicarboximide

6'-N-benzyloxycarbonylneamine
77967-96-5

6'-N-benzyloxycarbonylneamine

Conditions
ConditionsYield
In 1,4-dioxane; water at 20℃; for 6h;72%
endo-N-hydroxy-5-norbornene-2,3-dicarboximide O-bromoacetate
872054-82-5

endo-N-hydroxy-5-norbornene-2,3-dicarboximide O-bromoacetate

neomycin A
3947-65-7

neomycin A

N-6'-bromoacetylneamine
220874-82-8

N-6'-bromoacetylneamine

Conditions
ConditionsYield
In water; acetonitrile for 0.5h; sonication;70%
In water; acetone for 1h;70%
In water; acetone for 0.25h; Sonication;
In water; acetonitrile for 0.166667h; Product distribution / selectivity;
In water; acetone for 0.166667h;
Butyric acid (1R,2S,6R,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.02,6]dec-8-en-4-yl ester

Butyric acid (1R,2S,6R,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.02,6]dec-8-en-4-yl ester

neomycin A
3947-65-7

neomycin A

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-butyramide

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-butyramide

Conditions
ConditionsYield
In water; acetonitrile for 0.5h; sonication;70%
In water; acetonitrile at 20℃; for 0.5h;70 %Chromat.
Dodecanoic acid (1R,2S,6R,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.02,6]dec-8-en-4-yl ester

Dodecanoic acid (1R,2S,6R,7S)-3,5-dioxo-4-aza-tricyclo[5.2.1.02,6]dec-8-en-4-yl ester

neomycin A
3947-65-7

neomycin A

Dodecanoic acid [(2R,3S,4R,5R,6R)-5-amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-amide

Dodecanoic acid [(2R,3S,4R,5R,6R)-5-amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-amide

Conditions
ConditionsYield
In water; acetonitrile for 0.5h; sonication;70%
In water; acetonitrile at 20℃; for 0.5h;70 %Chromat.
neomycin A
3947-65-7

neomycin A

acetone O-<(vinyloxy)carbonyl>oxime
139705-38-7

acetone O-<(vinyloxy)carbonyl>oxime

{(1R,2S,3R,4R,5S)-4-[(2R,3R,4R,5S,6R)-4,5-Dihydroxy-3-vinyloxycarbonylamino-6-(vinyloxycarbonylamino-methyl)-tetrahydro-pyran-2-yloxy]-2,3-dihydroxy-5-vinyloxycarbonylamino-cyclohexyl}-carbamic acid vinyl ester
791064-36-3

{(1R,2S,3R,4R,5S)-4-[(2R,3R,4R,5S,6R)-4,5-Dihydroxy-3-vinyloxycarbonylamino-6-(vinyloxycarbonylamino-methyl)-tetrahydro-pyran-2-yloxy]-2,3-dihydroxy-5-vinyloxycarbonylamino-cyclohexyl}-carbamic acid vinyl ester

Conditions
ConditionsYield
With sodium hydroxide In phosphate buffer at 0℃; for 5h; pH=8.0;66%
neomycin A
3947-65-7

neomycin A

N-(t-butoxycarbonyloxy)-5-norbornene-endo-2,3-dicarboximide

N-(t-butoxycarbonyloxy)-5-norbornene-endo-2,3-dicarboximide

6'-N-(tert-Butoxycarbonyl)neamine
153953-67-4

6'-N-(tert-Butoxycarbonyl)neamine

Conditions
ConditionsYield
In 1,4-dioxane; water for 5h; Ambient temperature;65%
With triethylamine In 1,4-dioxane; water at 20℃; for 15.1667h;
2-acetoxy-(3ac,7ac)-3a,4,7,7a-tetrahydro-4r,7c-methano-isoindole-1,3-dione
24147-28-2

2-acetoxy-(3ac,7ac)-3a,4,7,7a-tetrahydro-4r,7c-methano-isoindole-1,3-dione

neomycin A
3947-65-7

neomycin A

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-acetamide

N-[(2R,3S,4R,5R,6R)-5-Amino-6-((1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxy-cyclohexyloxy)-3,4-dihydroxy-tetrahydro-pyran-2-ylmethyl]-acetamide

Conditions
ConditionsYield
In water; acetonitrile for 0.5h; sonication;60%
In water; acetone for 1h;60%
In water; acetonitrile at 20℃; for 0.5h;60%
Nα-[(thymin-1-yl)acetyl]-Nε-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl)-L-arginine

Nα-[(thymin-1-yl)acetyl]-Nε-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl)-L-arginine

neomycin A
3947-65-7

neomycin A

6'-N-[Nα-[(thymin-1-yl)acetyl]-Nε-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl)-DL-arginyl]neamine
886208-72-6

6'-N-[Nα-[(thymin-1-yl)acetyl]-Nε-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl)-DL-arginyl]neamine

Conditions
ConditionsYield
Stage #1: Nα-[(thymin-1-yl)acetyl]-Nε-(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl)-L-arginine With WSC*HCl In N,N-dimethyl-formamide for 3h;
Stage #2: neomycin A In water; N,N-dimethyl-formamide for 20h;
58.3%

3947-65-7Relevant academic research and scientific papers

New amphiphilic neamine conjugates bearing a metal binding motif active against MDR E.?aerogenes Gram-negative bacteria

Allam, Anas,Maigre, Laure,Alves de Sousa, Rodolphe,Dumont, Estelle,Vergalli, Julia,Pagès, Jean-Marie,Artaud, Isabelle

, p. 748 - 756 (2017)

Structure of bacterial envelope is one of the major factors contributing to Gram negative bacterial resistance. To develop new agents that target the bacterial membranes, we synthesized, by analogy with our previous peptide conjugates, new amphiphilic 3′,4′,6-trinaphthylmethylene neamines functionalized at position 5 through a short spacer by a chelating group, tris(2-pyridylmethyl)amine (TPA) and di-(picolyl)amine (DPA) and tetraazacyclotetradecane (Cyclam). ESI+mass spectrometry analyses showed that neither Zn(II)(NeaDPA) nor Cu(II)(NeaCyclam) were stable in the Mueller Hinton (MH) medium used for antibacterial assays. In contrast Zn(NeaTPA) was stable in the MH medium. Interestingly, in MH, the free ligand NeaTPA was found bound to zinc, the zinc salt being the most abundant salt in this medium. Thus, the antibacterial activities of all compounds were evaluated as free ligands against E.?coli strains, wild type AG100 and E.?aerogenes EA289 (a clinical MDR strain that overexpresses AcrAB-TolC efflux pump), as well as AG100A an AcrAB- E.?coli strain and EA298 a TolC- derivative. NeaCyclam and Zn(NeaTPA) were by far the most efficient compounds active against resistant isolate EA289 with MICs in the range 16–4 and 4?μM, respectively, while usual antibiotics such as β-lactams and phenicols were inactive (MICs?>?128) and ciprofloxacin was at 64?μM. Zn(NeaTPA) and NeaCyclam were shown to target and permeabilize the outer membrane of EA289 by promoting the cleavage of nitrocefin by periplasmic β-lactamase. Moreover, all the neamine conjugates were able to block the efflux of 1,2’-dinaphthylamine in EA289, by acting on the efflux transporter located in the inner membrane. These membranotropic properties contribute to explain the activities of these neamine conjugates toward the MDR EA289 strain.

Neamine Compositions and Methods of Use Thereof

-

Paragraph 0265, (2021/07/24)

Provided herein are compositions containing neamine, or a composition containing an agent that possesses one or more activities of neamine, and the research, diagnostic and therapeutic uses of such compounds, such as for the treatment of cancer.

Neamine and 2-deoxystreptamine neomycin derivatives exhibit antinociceptive activity in rat models of phasic, incision and neuropathic pain

Prado, Wiliam A.,Rossaneis, Ana C.,Carvalho, Ivone,Zamoner, Luis Otvio B.,Corrado, Alexandre P.

, p. 1696 - 1704 (2016/01/26)

Objectives To assess the antinociceptive activity of the neomycin derivatives neamine and 2-deoxystreptamine following intraspinal administration in rats. Methods We used the tail-flick test and measured the threshold to mechanical stimulation in models of incisional and neuropathic pain. Key findings The derivatives produced antinociception in the tail-flick test and reduced mechanical allodynia in models of incisional and neuropathic pain. The approximate ED50 in milligrams (confidence limits in parenthesis) in these tests were 1.35 mg (0.61; 2.95), 0.20 mg (0.14; 0.27) and 0.28 mg (0.12; 0.63) for neamine, and 1.05 mg (0.68; 1.60), 0.78 mg (0.776; 0.783) and 0.79 mg (0.46; 1.34) for 2-deoxystreptamine, respectively. Neamine was more potent than 2-deoxystreptamine in the incisional and neuropathic pain models, but they had similar potency in the tail-flick test. Tetra-azidoneamine, a neamine derivative in which free amino groups are replaced with azido groups, did not change the incisional mechanical allodynia. The reduction of incisional allodynia by neamine and 2-deoxystreptamine was transitorily antagonized by intrathecal administration of calcium chloride. Conclusions The intraspinal administration of neamine and 2-deoxystreptamine is antinociceptive in rats. The presence of amino groups in the structure of these derivatives is fundamental to their antinociceptive effect, which may be due to a calcium antagonist activity.

Neamine Compositions and Methods of Use Thereof

-

, (2011/11/06)

Provided herein are compositions containing neamine, or a composition containing an agent that possesses one or more activities of neamine, and the research, diagnostic and therapeutic uses of such compounds, such as for the treatment of cancer.

Structure-toxicity relationship of aminoglycosides: Correlation of 2′-amine basicity with acute toxicity in pseudo-disaccharide scaffolds

Chen, Lilach,Hainrichson, Mariana,Bourdetsky, Dmitry,Mor, Amram,Yaron, Sima,Baasov, Timor

body text, p. 8940 - 8951 (2009/04/03)

A new pseudo-disaccharide NB23 with a 3′,4′-methylidene protection was designed and its properties were evaluated in comparison to other two structurally related pseudo-disaccharides. The basicity of the 2′-amine was found to be well correlated to acute toxicity data in mice: the increase in the basicity is associated with the toxicity increase. Based on these data, a new pseudo-trisaccharide NB45 was constructed. NB45 exhibited significant antibacterial activity while at the same time retained low acute toxicity.

Design and synthesis of a structurally constrained aminoglycoside

Kling, Dale,Hesek, Dusan,Shi, Qicun,Mobashery, Shahriar

, p. 5450 - 5453 (2008/02/08)

(Chemical Equation Presented) The synthesis of a constrained tricyclic aminoglycoside derivative is described. This constrained compound fixes the spatial orientation of two critical rings for the minimal motif for binding to biological macromolecules such as RNA and proteins. Methanolysis of neomycin B under acidic conditions produced the bicyclic neamine. Transient protection by the Cu2+ ion and regioselective introduction of protective groups led to intermediate 7, which was used for a key annulation reaction that introduced the tricyclic nucleus into the structural framework. A final hydrogenolysis step to remove the protective groups produced the desired target molecule. The efficient eight-step synthesis was accomplished in 8% overall yield.

Synthesis of (+),(-)-neamine and their positional isomers as potential antibiotics

Ryu, Do Hyun,Tan, Choon-Hong,Rando, Robert R.

, p. 901 - 903 (2007/10/03)

The syntheses of (+)-neamine 1, (-)-neamine ent-1 and their positional isomers 2, 3, ent-2 and ent-3 are reported as potential new scaffolds for novel aminoglycoside antibiotics. These isomers exhibit similar inhibitory activities, as shown using an in vitro translation assay. A simple model is proposed to explain this lack of stereospecific binding to the ribosomal RNA.

AMINOGLYCOSIDE ANTIBIOTICS AND METHODS OF USING SAME

-

Page 31-34, (2008/06/13)

The present invention relates to aminoglycoside compounds having antibiotic activity. Moreover, the present invention relates to L-aminoglycoside compounds and diastereomers thereof which posses antibiotic activity and are not susceptible to development of resistant bacterial strains. The present invention also relates to methods of treatment and pharmaceutical compositions that utilize or comprise one or more of aminoglycoside compounds provided by the invention.

Synthesis of neamine libraries for RNA recognition using solution phase chemistry

Nunns, Claire L.,Spence, Lee A.,Slater, Martin J.,Berrisford, David J.

, p. 9341 - 9345 (2007/10/03)

Selective protection of the 6'-amino group of neamine allows the preparation of aminoglycoside libraries by reductive amination and Ugi multicomponent coupling.

Rapid combinatorial synthesis of aminoglycoside antibiotic mimetics: Use of a polyethylene glycol-linked amine and a neamine-derived aldehyde in multiple component condensation as a strategy for the discovery of new inhibitors of the HIV RNA Rev responsive element

Park, William K. C.,Auer, Manfred,Jaksche, Herbert,Wong, Chi-Huey

, p. 10150 - 10155 (2007/10/03)

A library of neomycin B mimetics has been prepared rapidly without chromatography using a neamine-derived aldehyde, tert-butyl isocyanide or isocyanoacetic acid methyl ester, a glycine-conjugated polyethylene glycol (PEG) methyl ether, and various Cbz-N-protected amino acids as substrates in a Ugi-type one-pot reaction. The product linked to PEG was isolated by precipitation in ether. A simultaneous base-catalyzed hydrolysis and de-O-acetylation followed by hydrogenation provided an easy access to a library of neomycin B mimetics, which were screened for binding to the Rev responsive element of HIV mRNA (RRE). Several products were found to be more active than neamine with the IC50 values in the micromolar range.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 3947-65-7